From: Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER
SOC | n | ROR (95%Cl) | PRR (χ2) | EBGM (EBGM05) | IC (IC025) |
---|---|---|---|---|---|
FAERS | |||||
General disorders and administration site conditions | 2296 | 1.68 (1.6–1.76)* | 1.5 (460.72) | 1.5 (1.44) | 0.58 (0.52)* |
Injury, poisoning and procedural complications | 2004 | 2.86 (2.72–3.01)* | 2.44 (1872.5)* | 2.44 (2.34)* | 1.28 (1.21)* |
Eye disorders | 2920 | 24.41 (23.35–25.52)* | 16.58 (43516.93)* | 16.54 (15.93)* | 4.05 (3.99)* |
JADER | |||||
Eye disorders | 138 | 154.03 (113.52–209)* | 46.83 (6246.83)* | 46.56 (34.31)* | 5.54 (3.86)* |